Latest news and press releases about Pasithea Therapeutics Corp. (KTTA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions.
Price
| Price | $0.49 |
| Market Cap | $16M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.07 |
| EV / EBITDA | 1958.83 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -49.49% |
| Return on Invested Capital | -48.04% |
| Return on Assets | -41.18% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AIM · CYCN · IBO · KALA · NBY · PLRZ · QNRX
Explore sector: Healthcare · Biotechnology
More sections of KTTA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks